1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024

Summary

Congenital hemophilia A and B are bleeding disorders that are caused by genetic X-linked deficiencies in the blood clotting Factors VIII and IX, respectively. Hemophilia manifests as mild, moderate, or severe inability to form clots, depending upon the endogenous levels of circulating factor in an individual patient. The mainstay of treatment for hemophilia is to replace the missing FVIII or FIX, produced using plasma-derived or recombinant methods. Some patients develop inhibitors to FVIII or FIX treatment and need a bypassing agent, such as FVIIa, to resolve bleeds. Patients of hemophilia A or B often require lifelong treatment to prevent and control bleeding episodes, and this therefore represents a lucrative sales opportunity.

GlobalData estimates the 2014 sales for recombinant hemophilia A and B markets at approximately $5.38 billion across the 7MM+A covered in this report. The market is expected to reach $6.25 billion in 2024 at a CAGR of 1.52%. This growth will be mainly driven by an increasing use of routine prophylaxis and a greater use of recombinant products in place of plasma-derived therapies.

The hemophilia recombinant treatment pipeline is strong, and crowded with multiple long-acting recombinant clotting factors; however, GlobalData expects a lack of initiative for hemophilia A patients to switch to long-acting rFVIII, and a limited scope for premium pricing for new agents, restraining the market growth. Overall, Baxalta is expected to remain as the market leader in the hemophilia space throughout the forecast period, dominating the market with its current gold standard therapy for hemophilia A, Advate, supported by the launch its of pegylated rFVIII, Adynovate.

Highlights

Key Questions Answered

- What will be the impact of the new long-acting rFVIII and rFIX products in the hemophilia market sales? Led by Biogen’s Eloctate and Alprolix, moderate and high rates of adoption of the long-acting rFVIII and rFIX therapies, respectively, are expected.
- With the growing importance of long-acting Factors, what are the strategies of the companies that have short-acting assets to remain competitive? What are the other approaches that new entrants employ?
- Prevention of inhibitor formation remains as a major unmet need in the hemophilia space. What are the other unmet needs and opportunities in the hemophilia market?

Key Findings

- One of the main drivers of the expansion of the hemophilia recombinant market will be the increasing use of routine prophylaxis in pediatric and adult hemophilia A and B patients. Prophylactic regimens have demonstrated improvements in the prevention of bleeding episodes and joint damage. In the 7MM, routine prophylaxis is the standard of care for severe hemophilia patients.
- The high cost of rFVIII and rFIX therapies is a significant barrier to market growth. Scope for premium pricing for new entrants in the hemophilia A and B market is limited. GlobalData believes that Biogen has set an upper limit to the price of long-acting rFVIII and rFIX products with its competitive pricing strategy for Eloctate and Alprolix.
- Companies are focusing on the development of therapies that can further reduce the dosing frequency required for prophylaxis. Strategies to prevent inhibitor formation are also sought. Early-stage pipeline products that employ monoclonal antibodies, RNA interference, and gene therapies appear to be highly promising, and represent a huge threat, if they are approved, for the existing treatment options.

Scope

- Overview of hemophilia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized hemophilia recombinant therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in six patient segments (including on-demand, prophylactic, and inhibitor), forecast from 2014 to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the hemophilia recombinant therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for different lines of therapy. The most promising candidate in Phase III development is profiled.
- Analysis of the current and future market competition in the global hemophilia recombinant therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hemophilia recombinant therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global hemophilia recombinant therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Hemophilia A and B Recombinant Factor Replacement Therapy - Global Drug Forecast and Market Analysis to 2024
1 Table of Contents
1 Table of Contents 9
1.1 List of Tables 16
1.2 List of Figures 21
2 Introduction 23
2.1 Catalyst 23
2.2 Related Reports 24
2.3 Upcoming Related Reports 24
3 Disease Overview 25
3.1 Etiology and Pathophysiology 25
3.1.1 Etiology 25
3.1.2 Pathophysiology 26
3.1.3 Prognosis and Quality of Life 28
3.2 Symptoms 29
3.2.1 Hemophilia A and B 29
3.2.2 Inhibitors 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 32
4.3 Global Trends 33
4.4 Forecast Methodology 35
4.4.1 Sources Used 35
4.4.2 Sources Not Used 36
4.4.3 Forecast Assumptions and Methods 37
4.5 Epidemiological Forecast for Hemophilia A (2014-2024) 41
4.5.1 Diagnosed Prevalent Cases of Hemophilia A 41
4.5.2 Diagnosed Prevalent Cases of Hemophilia A by Age 42
4.5.3 Diagnosed Prevalent Cases of Hemophilia A by Sex 44
4.5.4 Age-Standardized Diagnosed Prevalence of Hemophilia A 46
4.6 Epidemiological Forecast for Hemophilia B (2014-2024) 47
4.6.1 Diagnosed Prevalent Cases of Hemophilia B 47
4.6.2 Diagnosed Prevalent Cases of Hemophilia B by Age 49
4.6.3 Diagnosed Prevalent Cases of Hemophilia B by Sex 51
4.6.4 Age-Standardized Diagnosed Prevalence of Hemophilia B 53
4.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2014-2024) 54
4.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 54
4.7.2 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex 56
4.8 Discussion 58
4.8.1 Conclusions on Epidemiological Trends 58
4.8.2 Limitations of the Analysis 59
4.8.3 Strengths of the Analysis 60
5 Disease Management 61
5.1 Treatment Overview 61
5.1.1 Hemophilia A and B Diagnosis 61
5.1.2 Hemophilia A and B Treatment 62
5.1.3 Diagnosis of Inhibitors 64
5.1.4 Treatment of Inhibitors 65
5.2 US 67
5.2.1 Clinical Practice 67
5.3 France 69
5.3.1 Clinical Practice 69
5.4 Germany 71
5.4.1 Clinical Practice 71
5.5 Italy 73
5.5.1 Clinical Practice 73
5.6 Spain 75
5.6.1 Clinical Practice 75
5.7 UK 77
5.7.1 Clinical Practice 77
5.8 Japan 79
5.8.1 Clinical Practice 79
5.9 Argentina 81
5.9.1 Clinical Practice 81
6 Competitive Assessment 83
6.1 Overview 83
6.2 Strategic Competitive Assessment 83
6.3 Product Profiles - Hemophilia A 86
6.3.1 Advate (Octocog Alfa) 86
6.3.2 Kogenate FS/Helixate FS (Octocog Alfa) 92
6.3.3 Xyntha/ReFacto AF (Moroctocog Alfa) 99
6.3.4 Recombinate (Octocog Alfa) 103
6.3.5 Eloctate (Efmoroctocog Alfa) 107
6.3.6 NovoEight (Turoctocog Alfa) 113
6.3.7 Nuwiq (Simoctocog Alfa) 118
6.4 Product Profiles - Hemophilia B 123
6.4.1 BeneFIX (Nonacog Alfa) 123
6.4.2 Alprolix (Eftrenonacog Alfa) 128
6.4.3 Rixubis (Nonacog Gamma) 134
6.4.4 IXinity (Trenonacog Alfa) 138
6.5 Product Profiles - Hemophilia A and B with Inhibitors 143
6.5.1 NovoSeven RT (Eptacog Alfa) 143
7 Opportunity and Unmet Need 149
7.1 Overview 149
7.2 Opportunity Analysis 150
7.2.1 Longer-Lasting Recombinant Factors 150
7.2.2 Lower-Cost Recombinant Replacement Therapies 151
7.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 153
7.2.4 More Convenient Drug Administration 154
7.3 Unmet Needs Gap Analysis 154
7.3.1 Long-Acting FVIII Replacement Therapies 154
7.3.2 Gene Therapy Treatments for Hemophilia A and B 155
8 Pipeline Assessment 157
8.1 Overview 157
8.2 Late-Stage Development Candidates - Hemophilia A 158
8.2.1 Kovaltry (Octocog Alfa; BAY 81-8973) 159
8.2.2 Adynovate (BAX-855) 164
8.2.3 BAY 94-9027 (Damoctocog Alfa Pegol) 169
8.2.4 N8-GP (Turoctocog Alfa Pegol) 175
8.2.5 CSL-627 (rFVIII-SC) 181
8.2.6 GreenGene F (Beroctocog Alfa; GC1101C) 186
8.3 Late-Stage Development Candidates - Hemophilia B 192
8.3.1 CSL-654 (rIX-FP; Albutrepenonacog Alfa) 193
8.3.2 N9-GP (NN-7999; Nonacog Beta Pegol) 197
8.4 Late-Stage Development Candidates - Hemophilia A and B Bypassing Agents (Patients with Inhibitors) 203
8.4.1 BAX-817 (rFVIIa BI) 204
8.4.2 LR-769 (rhFVIIa) 209
8.4.3 CSL-689 (rVIIa-FP) 215
8.5 Promising Drugs in Early-Stage Development 220
8.5.1 Alternative Coagulation Promoters 220
8.5.2 Gene Therapies 223
9 Current and Future Players 227
9.1 Overview 227
9.2 Trends in Corporate Strategy 229
9.3 Company Profiles 229
9.3.1 Baxalta 229
9.3.2 Bayer 233
9.3.3 Biogen 235
9.3.4 CSL Behring 237
9.3.5 Novo Nordisk 239
9.3.6 Pfizer 242
10 Market Outlook 244
10.1 Global Markets 244
10.1.1 Forecast 244
10.1.2 Drivers and Barriers - Global Market 247
10.2 US 250
10.2.1 Forecast 250
10.2.2 Key Events 254
10.2.3 Drivers and Barriers 254
10.3 5EU 255
10.3.1 Forecast 255
10.3.2 Key Events 259
10.3.3 Drivers and Barriers - France 260
10.3.4 Drivers and Barriers - Germany 262
10.3.5 Drivers and Barriers - Italy 263
10.3.6 Drivers and Barriers - Spain 264
10.3.7 Drivers and Barriers - UK 265
10.4 Japan 266
10.4.1 Forecast 266
10.4.2 Key Events 270
10.4.3 Drivers and Barriers 270
10.5 Argentina 272
10.5.1 Forecast 272
10.5.2 Key Events 277
10.5.3 Drivers and Barriers 277
11 Appendix 279
11.1 Bibliography 279
11.2 Abbreviations 306
11.3 Methodology 309
11.4 Forecasting Methodology 309
11.4.1 Diagnosed Hemophilia Patients 309
11.4.2 Percent Drug-Treated Patients 310
11.4.3 Drugs Included in Each Therapeutic Class 310
11.4.4 Launch Dates 311
11.4.5 General Pricing Assumptions 312
11.4.6 Individual Drug Assumptions 313
11.4.7 Pricing of Pipeline Agents 322
11.5 Primary Research - KOLs Interviewed for this Report 323
11.6 Primary Research - Prescriber Survey 327
11.7 Real-World Data 327
11.8 About the Authors 329
11.8.1 Analyst 329
11.8.2 Therapy Area Director 329
11.8.3 Epidemiologists 329
11.8.4 Global Head of Healthcare 331
11.9 About GlobalData 332
11.10 Disclaimer 332

1.1 List of Tables
Table 1: Symptoms of Hemophilia A and B 30
Table 2: Relationship of Bleeding Severity with Clotting Factor Level 31
Table 3: Hemophilia - Risk Factors and Comorbidities 33
Table 4: 9MM, Diagnosed Prevalence of Hemophilia A (per 100,000 Population), Both Sexes, All Ages, 2004-2013 34
Table 5: 9MM, Diagnosed Prevalence of Hemophilia B (per 100,000 Population), Both Sexes, All Ages, 2004-2013 34
Table 6: 9MM, Sources and Diagnosed Prevalence Data for Hemophilia A and B 35
Table 7: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024 41
Table 8: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, Row (%), 2014 43
Table 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, Row (%), 2014 45
Table 10: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024 48
Table 11: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, Row (%), 2014 50
Table 12: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, Row (%), 2014 52
Table 13: 9MM, Diagnosed Prevalent Cases of Hemophilia, Both Sexes, All Ages, N, 2014-2024 55
Table 14: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, Row (%), 2014 57
Table 15: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2015 62
Table 16: Country Profile - US, 2014 67
Table 17: Country Profile - France, 2014 69
Table 18: Country Profile - Germany, 2014 71
Table 19: Country Profile - Italy, 2014 73
Table 20: Country Profile - Spain, 2014 75
Table 21: Country Profile - UK, 2014 77
Table 22: Country Profile - Japan, 2014 79
Table 23: Country Profile - Argentina, 2014 81
Table 24: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2015 86
Table 25: Product Profile - Advate 87
Table 26: Advate SWOT Analysis, 2015 90
Table 27: Global Sales Forecast ($m) for Advate, 2014-2024 91
Table 28: Product Profile - Kogenate FS/Helixate FS 92
Table 29: Kogenate FS/Helixate FS SWOT Analysis, 2015 97
Table 30: Global Sales Forecast ($m) for Kogenate FS/Kogenate Bayer, 2014-2024 98
Table 31: Global Sales Forecast ($m) for Helixate FS/Helixate NexGen, 2014-2024 99
Table 32: Product Profile - Xyntha/ReFacto AF 100
Table 33: Xyntha/ReFacto AF SWOT Analysis, 2015 102
Table 34: Global Sales Forecast ($m) for Xyntha/ReFacto AF, 2014-2024 103
Table 35: Product Profile - Recombinate 104
Table 36: Recombinate SWOT Analysis, 2015 106
Table 37: Global Sales Forecast ($m) for Recombinate, 2014-2024 107
Table 38: Product Profile - Eloctate 108
Table 39: Eloctate SWOT Analysis, 2015 112
Table 40: Global Sales Forecast ($m) for Eloctate, 2014-2024 113
Table 41: Product Profile - NovoEight 114
Table 42: NovoEight SWOT Analysis, 2015 117
Table 43: Global Sales Forecast ($m) for NovoEight, 2014-2024 118
Table 44: Product Profile - Nuwiq 119
Table 45: Nuwiq SWOT Analysis, 2015 122
Table 46: Global Sales Forecast ($m) for Nuwiq, 2014-2024 123
Table 47: Product Profile - BeneFIX 124
Table 48: BeneFIX SWOT Analysis, 2015 127
Table 49: Global Sales Forecast ($m) for BeneFIX, 2014-2024 128
Table 50: Product Profile - Alprolix 129
Table 51: Alprolix SWOT Analysis, 2015 132
Table 52: Global Sales Forecast ($m) for Alprolix, 2014-2024 134
Table 53: Product Profile - Rixubis 135
Table 54: Rixubis SWOT Analysis, 2015 137
Table 55: Global Sales Forecast ($m) for Rixubis, 2014-2024 138
Table 56: Product Profile - IXinity 139
Table 57: IXinity SWOT Analysis, 2015 142
Table 58: Global Sales Forecast ($m) for IXinity, 2014-2024 143
Table 59: Product Profile - NovoSeven RT 144
Table 60: NovoSeven RT SWOT Analysis, 2015 147
Table 61: Global Sales Forecast ($m) for NovoSeven RT, 2014-2024 148
Table 62: Overall Unmet Needs - Current Level of Attainment 150
Table 63: Hemophilia A - Phase III Pipeline, 2015 158
Table 64: Product Profile - Kovaltry 160
Table 65: Kovaltry SWOT Analysis, 2015 163
Table 66: Global Sales Forecast ($m) for Kovaltry, 2014-2024 164
Table 67: Product Profile - Adynovate 165
Table 68: Adynovate SWOT Analysis, 2015 168
Table 69: Global Sales Forecast ($m) for Adynovate, 2014-2024 169
Table 70: Product Profile - BAY 94-9027 170
Table 71: Efficacy of BAY 94-9027 in the PROTECT VIII study 171
Table 72: BAY 94-9027 SWOT Analysis, 2015 174
Table 73: Global Sales Forecast ($m) for BAY 94-9027, 2014-2024 175
Table 74: Product Profile - N8-GP 176
Table 75: N8-GP SWOT Analysis, 2015 180
Table 76: Global Sales Forecast ($m) for N8-GP, 2014-2024 181
Table 77: Product Profile - CSL-627 182
Table 78: CSL-627 SWOT Analysis, 2015 185
Table 79: Global Sales Forecast ($m) for CSL-627, 2014-2024 186
Table 80: Product Profile - GreenGene F 187
Table 81: GreenGene F SWOT Analysis, 2015 190
Table 82: Global Sales Forecast ($m) for GreenGene F, 2014-2024 191
Table 83: Hemophilia B - Phase III Pipeline, 2015 192
Table 84: Product Profile - CSL-654 193
Table 85: CSL-654 SWOT Analysis, 2015 196
Table 86: Global Sales Forecast ($m) for CSL-654, 2014-2024 197
Table 87: Product Profile - N9-GP 198
Table 88: N9-GP SWOT Analysis, 2015 202
Table 89: Global Sales Forecast ($m) for N9-GP, 2014-2024 203
Table 90: Hemophilia A and B with Inhibitors - Phase III Pipeline, 2015 203
Table 91: Product Profile - BAX-817 205
Table 92: BAX-817 SWOT Analysis, 2015 208
Table 93: Global Sales Forecast ($m) for BAX-817, 2014-2024 209
Table 94: Product Profile - LR-769 210
Table 95: LR-769 SWOT Analysis, 2015 214
Table 96: Global Sales Forecast ($m) for LR-769, 2014-2024 215
Table 97: Product Profile - CSL-689 216
Table 98: CSL-689 SWOT Analysis, 2015 219
Table 99: Global Sales Forecast ($m) for CSL-689, 2014-2024 220
Table 100: Alternative Coagulation Promoters - Early-Stage Pipeline, 2015 223
Table 101: Hemophilia A and B Gene Therapies - Early-Stage Pipeline, 2015 225
Table 102: Key Companies in the Hemophilia A and B Recombinant Therapies Market, 2014-2024 228
Table 103: Baxalta's Hemophilia Recombinant Portfolio Assessment, 2015 232
Table 104: Baxalta SWOT Analysis, 2015 233
Table 105: Bayer's Hemophilia Recombinant Portfolio Assessment, 2015 234
Table 106: Bayer SWOT Analysis, 2015 235
Table 107: Biogen's Hemophilia Recombinant Portfolio Assessment, 2015 236
Table 108: Biogen SWOT Analysis, 2015 237
Table 109: CSL Behring's Hemophilia Recombinant Portfolio Assessment, 2015 238
Table 110: CSL Behring SWOT Analysis, 2015 239
Table 111: Novo Nordisk's Hemophilia Recombinant Portfolio Assessment, 2015 241
Table 112: Novo Nordisk SWOT Analysis, 2015 242
Table 113: Pfizer's Hemophilia Recombinant Portfolio Assessment, 2015 243
Table 114: Pfizer SWOT Analysis, 2015 243
Table 115: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the 7MM+A, 2014-2024 246
Table 116: Global Hemophilia A and B Market - Drivers and Barriers, 2014-2024 247
Table 117: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in the US, 2014-2024 252
Table 118: Key Events Impacting Sales for Hemophilia A and B in the US, 2014-2024 254
Table 119: US Hemophilia A and B Market - Drivers and Barriers, 2014-2024 254
Table 120: Sales Forecasts ($m) for Hemophilia A and B Recombinant Therapies in the 5EU, 2014-2024 257
Table 121: Key Events Impacting Sales for Hemophilia A and B Recombinant Therapies in the 5EU, 2014-2024 259
Table 122: French Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024 260
Table 123: German Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024 262
Table 124: Italian Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024 263
Table 125: Spanish Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024 264
Table 126: UK Hemophilia A and B Recombinant Therapies Market - Drivers and Barriers, 2014-2024 265
Table 127: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in Japan, 2014-2024 268
Table 128: Key Events Impacting Sales for Hemophilia A and B in Japan, 2014-2024 270
Table 129: Japanese Hemophilia A and B Market - Drivers and Barriers, 2014-2024 270
Table 130: Sales Forecast ($m) for Hemophilia A and B Recombinant Therapies in Argentina, 2014-2024 275
Table 131: Key Events Impacting Sales for Hemophilia A and B in Argentina, 2014-2024 277
Table 132: Argentine Hemophilia A and B Market - Drivers and Barriers, 2014-2024 277
Table 133: Key Launch Dates 311
Table 134: Physicians Surveyed 327

1.2 List of Figures
Figure 1: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2014-2024 42
Figure 2: 9MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, by Age, N, 2014 44
Figure 3: 9MM, Diagnosed Prevalent Cases of Hemophilia A, by Sex, All Ages, N, 2014 46
Figure 4: 9MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (per 100,000 Population), by Sex, 2014 47
Figure 5: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2014-2024 49
Figure 6: 9MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, by Age, N, 2014 51
Figure 7: 9MM, Diagnosed Prevalent Cases of Hemophilia B, by Sex, All Ages, N, 2014 53
Figure 8: 9MM, Age-Standardized Prevalence of Diagnosed Hemophilia B (per 100,000 Population), by Sex, 2014 54
Figure 9: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2014-2024 56
Figure 10: 9MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Sex, All Ages, N, 2014 58
Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2014-2024 159
Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia B, 2014-2024 192
Figure 13: Competitive Assessment of Late-Stage Pipeline Agents for Hemophilia A and B Patients with Inhibitors, 2014-2024 204
Figure 14: Company Portfolio Analysis in Hemophilia A and B, 2014-2024 227
Figure 15: Global Sales for Hemophilia A and B Recombinant Therapies by Region, 2014-2024 247
Figure 16: Sales for Hemophilia A and B recombinant therapies in the US by Drug Class, 2014-2024 253
Figure 17: Sales for Hemophilia A and B Recombinant Therapies in the 5EU by Drug Class, 2014-2024 258
Figure 18: Sales for Hemophilia A and B Recombinant Therapies in Japan by Drug Class, 2014-2024 269
Figure 19: Sales for Hemophilia A and B Recombinant Therapies in Argentina by Drug Class, 2014-2024 276

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.